Literature DB >> 29083055

Hormonal Regulation of Osteocyte Perilacunar and Canalicular Remodeling in the Hyp Mouse Model of X-Linked Hypophosphatemia.

Danielle Tokarz1,2, Janaina S Martins2,3, Elizabeth T Petit3, Charles P Lin1,2, Marie B Demay2,3, Eva S Liu2,3,4.   

Abstract

Osteocytes remodel their surrounding perilacunar matrix and canalicular network to maintain skeletal homeostasis. Perilacunar/canalicular remodeling is also thought to play a role in determining bone quality. X-linked hypophosphatemia (XLH) is characterized by elevated serum fibroblast growth factor 23 (FGF23) levels, resulting in hypophosphatemia and decreased production of 1,25 dihydroxyvitamin D (1,25D). In addition to rickets and osteomalacia, long bones from mice with XLH (Hyp) have impaired whole-bone biomechanical integrity accompanied by increased osteocyte apoptosis. To address whether perilacunar/canalicular remodeling is altered in Hyp mice, histomorphometric analyses of tibia and 3D intravital microscopic analyses of calvaria were performed. These studies demonstrate that Hyp mice have larger osteocyte lacunae in both the tibia and calvaria, accompanied by enhanced osteocyte mRNA and protein expression of matrix metalloproteinase 13 (MMP13) and genes classically used by osteoclasts to resorb bone, such as cathepsin K (CTSK). Hyp mice also exhibit impaired canalicular organization, with a decrease in number and branching of canaliculi extending from tibial and calvarial lacunae. To determine whether improving mineral ion and hormone homeostasis attenuates the lacunocanalicular phenotype, Hyp mice were treated with 1,25D or FGF23 blocking antibody (FGF23Ab). Both therapies were shown to decrease osteocyte lacunar size and to improve canalicular organization in tibia and calvaria. 1,25D treatment of Hyp mice normalizes osteocyte expression of MMP13 and classic osteoclast markers, while FGF23Ab decreases expression of MMP13 and selected osteoclast markers. Taken together, these studies point to regulation of perilacunar/canalicular remodeling by physiologic stimuli including hypophosphatemia and 1,25D.
© 2017 American Society for Bone and Mineral Research. © 2017 American Society for Bone and Mineral Research.

Entities:  

Keywords:  BONE HISTOMORPHOMETRY; BONE REMODELING; OSTEOCYTES; OSTEOMALACIA AND RICKETS; PTH/VIT D/FGF23

Mesh:

Substances:

Year:  2017        PMID: 29083055      PMCID: PMC6005377          DOI: 10.1002/jbmr.3327

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  50 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Demonstration of osteocytic perilacunar/canalicular remodeling in mice during lactation.

Authors:  Hai Qing; Laleh Ardeshirpour; Paola Divieti Pajevic; Vladimir Dusevich; Katharina Jähn; Shigeaki Kato; John Wysolmerski; Lynda F Bonewald
Journal:  J Bone Miner Res       Date:  2012-05       Impact factor: 6.741

3.  Parathyroid hormone increases the expression level of matrix metalloproteinase-13 in vivo.

Authors:  M Uchida; H Yamato; Y Nagai; H Yamagiwa; T Hayami; K Tokunaga; N Endo; H Suzuki; K Obara; A Fujieda; H Murayama; S Fukumoto
Journal:  J Bone Miner Metab       Date:  2001       Impact factor: 2.626

4.  Vitamin D regulates osteocyte survival and perilacunar remodeling in human and murine bone.

Authors:  Tim Rolvien; Matthias Krause; Anke Jeschke; Timur Yorgan; Klaus Püschel; Thorsten Schinke; Björn Busse; Marie B Demay; Michael Amling
Journal:  Bone       Date:  2017-06-27       Impact factor: 4.398

5.  Mutational analysis of the PEX gene in patients with X-linked hypophosphatemic rickets.

Authors:  I A Holm; X Huang; L M Kunkel
Journal:  Am J Hum Genet       Date:  1997-04       Impact factor: 11.025

6.  Effects of altered diet on serum levels of 1,25-dihydroxyvitamin D and parathyroid hormone in X-linked hypophosphatemic (Hyp and Gy) mice.

Authors:  R A Meyer; M H Meyer; P L Morgan
Journal:  Bone       Date:  1996-01       Impact factor: 4.398

7.  1α,25-dihydroxyvitamin D3 stimulates human SOST gene expression and sclerostin secretion.

Authors:  Asiri R Wijenayaka; Dongqing Yang; Matthew Prideaux; Nobuaki Ito; Masakazu Kogawa; Paul H Anderson; Howard A Morris; Lucian B Solomon; Gabriela G Loots; David M Findlay; Gerald J Atkins
Journal:  Mol Cell Endocrinol       Date:  2015-06-23       Impact factor: 4.102

8.  Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2.

Authors:  Masakazu Kogawa; Asiri R Wijenayaka; Renee T Ormsby; Gethin P Thomas; Paul H Anderson; Lynda F Bonewald; David M Findlay; Gerald J Atkins
Journal:  J Bone Miner Res       Date:  2013-12       Impact factor: 6.741

9.  Overexpression of Bcl2 in osteoblasts inhibits osteoblast differentiation and induces osteocyte apoptosis.

Authors:  Takeshi Moriishi; Zenjiro Maruyama; Ryo Fukuyama; Masako Ito; Toshihiro Miyazaki; Hideki Kitaura; Hidetake Ohnishi; Tatsuya Furuichi; Yosuke Kawai; Ritsuko Masuyama; Hisato Komori; Kenji Takada; Hiroshi Kawaguchi; Toshihisa Komori
Journal:  PLoS One       Date:  2011-11-17       Impact factor: 3.240

Review 10.  Osteocytic osteolysis: time for a second look?

Authors:  John J Wysolmerski
Journal:  Bonekey Rep       Date:  2012-12-05
View more
  19 in total

Review 1.  Investigating Osteocytic Perilacunar/Canalicular Remodeling.

Authors:  Cristal S Yee; Charles A Schurman; Carter R White; Tamara Alliston
Journal:  Curr Osteoporos Rep       Date:  2019-08       Impact factor: 5.096

Review 2.  The Osteocyte: New Insights.

Authors:  Alexander G Robling; Lynda F Bonewald
Journal:  Annu Rev Physiol       Date:  2020-02-10       Impact factor: 19.318

3.  Dentoalveolar Defects in the Hyp Mouse Model of X-linked Hypophosphatemia.

Authors:  H Zhang; M B Chavez; T N Kolli; M H Tan; H Fong; E Y Chu; Y Li; X Ren; K Watanabe; D G Kim; B L Foster
Journal:  J Dent Res       Date:  2020-01-24       Impact factor: 6.116

4.  Chronic kidney disease and aging differentially diminish bone material and microarchitecture in C57Bl/6 mice.

Authors:  Chelsea M Heveran; Charles A Schurman; Claire Acevedo; Eric W Livingston; Danielle Howe; Eric G Schaible; Heather B Hunt; Adam Rauff; Eve Donnelly; R Dana Carpenter; Moshe Levi; Anthony G Lau; Ted A Bateman; Tamara Alliston; Karen B King; Virginia L Ferguson
Journal:  Bone       Date:  2019-05-02       Impact factor: 4.398

5.  Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD.

Authors:  Erica L Clinkenbeard; Megan L Noonan; Joseph C Thomas; Pu Ni; Julia M Hum; Mohammad Aref; Elizabeth A Swallow; Sharon M Moe; Matthew R Allen; Kenneth E White
Journal:  JCI Insight       Date:  2019-02-21

6.  In Vivo 3D Histomorphometry Quantifies Bone Apposition and Skeletal Progenitor Cell Differentiation.

Authors:  Shu-Chi A Yeh; Katarzyna Wilk; Charles P Lin; Giuseppe Intini
Journal:  Sci Rep       Date:  2018-04-03       Impact factor: 4.379

7.  Effects of Active Vitamin D or FGF23 Antibody on Hyp Mice Dentoalveolar Tissues.

Authors:  E J Lira Dos Santos; M B Chavez; M H Tan; F F Mohamed; T N Kolli; B L Foster; E S Liu
Journal:  J Dent Res       Date:  2021-04-27       Impact factor: 6.116

Review 8.  FGF23 signalling and physiology.

Authors:  Bryan B Ho; Clemens Bergwitz
Journal:  J Mol Endocrinol       Date:  2021-02       Impact factor: 5.098

Review 9.  Potential Role of Perilacunar Remodeling in the Progression of Osteoporosis and Implications on Age-Related Decline in Fracture Resistance of Bone.

Authors:  Katharina Jähn-Rickert; Elizabeth A Zimmermann
Journal:  Curr Osteoporos Rep       Date:  2021-06-12       Impact factor: 5.096

10.  Sclerostin Directly Stimulates Osteocyte Synthesis of Fibroblast Growth Factor-23.

Authors:  Nobuaki Ito; Matthew Prideaux; Asiri R Wijenayaka; Dongqing Yang; Renee T Ormsby; Lynda F Bonewald; Gerald J Atkins
Journal:  Calcif Tissue Int       Date:  2021-02-22       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.